Ibrutinib and ABT199 for CLL

Jennifer Brown, MD, PhD

Video Categories: ASH 2014

Jennifer R. Brown, MD, PhD, at Dana-Farber Cancer Institute in Boston, discusses what she believes are the most important items coming out of ASH for CLL this year. She mentions excellent study results being presented about the drugs ibrutinib and ABT199.

Related Videos

September 7, 2018

The Future of Genomics and Targeted Therapies

Dr Andrey Antov muses on the evolution of genomics and how it could potentially impact targeted therapies and cancer care.

September 20, 2013

The Pricing Evolution of Personalized Medicines

Grant Lawless discusses the changing landscape of pricing personalized medicines